According to sources from Biohaven Pharmaceutical Holding Company Ltd, the company was spotted claiming that two doses of its experimental treatment for acute migraine were effective in reducing headaches in a pivotal study.
The drug, vazegepant, belongs to a new class of treatments for migraine called CGRP inhibitors.
This drug is the first CGRP treatment delivered in an intranasal formulation, which tends to benefit the patients who are uncomfortable with needles, claims the company. Within the trial period, the drug was tested in 3 varied phases. Two higher doses reduced pain, helping patients return to normal function within two hours.
The positive results allow Biohaven to accelerate the program with only one additional positive efficacy trial likely needed for submission, the company said.
The FDA is planned to settle on the organization’s lead item for intense treatment of migraine, rimegepant, by the 2020’s first quarter. Rimegepant, which is another CGRP inhibitor, is additionally being tried for aversion of migraine. Vazegepant is corresponding to rimegepant and has cooperative energies with the item regarding showcasing, assets, and deals power, SVB Leerink examiner Marc Goodman said.